Journal article

The right place for Sulphonylureas today.

David R Webb, Melanie J Davies, Janet Jarvis, Sam Seidu, Kamlesh Khunti

Diabetes Research and Clinical Practice | Published : 2019


The place of Sulphonylurea based insulin secretagogues in the management of Type 2 diabetes appears as controversial today as it was fifty years ago. Newer therapies are associated with less hypoglycaemia and weight gain than Sulphonylureas but currently cost more and lack assurances which come with long-term exposure. Emergence of recent CVOT data for SGLT-2 inhibitors and GLP-1 receptor agonists is likely to influence therapeutic choices and guidance is now supportive of their earlier use in cases at high risk of cardiovascular disease. Meta-analyses of Sulphonylurea trials have failed to indicate a consistent effect (positive or negative) on cardiovascular disease or mortality, although a..

View full abstract

University of Melbourne Researchers